GTsetu

EN ISO 10993 Biological Evaluation of Medical Devices: Complete Guide 2026 | GTsetu
Home  ›  Compliance Standards  ›  EN ISO 10993 Guide
🧬 Medical Device Biological Evaluation Guide 2026

EN ISO 10993: Biological Evaluation of Medical Devices

Direct Answer: EN ISO 10993 is the series of standards for evaluating the biological safety of medical devices. ISO 10993-1 sets the framework, within a risk management process, and later parts cover specific tests and assessments. It is a conformity framework, not a registrar certificate. Demonstrating compliance follows 5 steps: Preparation (device categorisation by body contact and duration), Documentation (biological evaluation plan and characterisation), Testing (only the endpoints needed, at competent laboratories), Internal Review (gap closure and risk file update) and Reporting & Submission (biological evaluation report in your regulatory file). Typical programmes take 3–18 months depending on device risk.

📅 November 3, 2026⏱ 15 min read✍️ GT Setu Editorial Team🔄 Updated regularly
20+
Parts in the ISO 10993 Series
5
Key Steps to Conformity
3–18
Months (Indicative Timeline)
0%
GTsetu Broker Commission

EN ISO 10993 is the family of standards for the biological evaluation of medical devices. It helps manufacturers show that device materials and finished products do not cause unacceptable biological harm, such as toxicity, irritation, sensitisation or blood-related reactions. The European EN ISO adoption is what notified bodies reference under EU rules, while the international ISO version is widely used elsewhere.

Biological evaluation sits inside your wider compliance system: a ISO 13485 quality management system, ISO 14971 risk management and, for many manufacturers, ISO 9001 processes. This guide explains the full route from device categorisation to the biological evaluation report. See also partnership evaluation criteria and business verification for supplier due diligence.

📋 Who Is This Guide For?

This guide is for regulatory affairs managers, quality and R&D leads, and device manufacturers, as well as component and material suppliers who are asked for biocompatibility data. It covers the evidence-based route and the consultant-led route. Related reading: supplier collaboration platforms and distributors and manufacturers.

SECTION 1

1 What Is EN ISO 10993 & Why It Matters

🧬 The Standard Explained

EN ISO 10993 is a series titled Biological evaluation of medical devices. ISO 10993-1 describes the evaluation and testing within a risk management process, covering device categorisation, relevant biological endpoints and the need for a structured evaluation. Other parts cover specific tests (such as cytotoxicity and sensitisation), chemical characterisation, toxicological risk assessment and sample preparation. The current edition of Part 1 is recent, so check the latest status on the ISO and CEN catalogues before planning. The approach is risk-based: you use existing data first and test only where gaps remain.

🌐

Global Regulatory Acceptance

Regulators in many regions, including those applying EU and US requirements, expect a biological evaluation aligned with ISO 10993.

🛡️

Patient Safety

The series is designed to identify biological hazards early, before devices reach patients.

🧪

Risk-Based, Not Test-Everything

Material data, chemical characterisation and toxicological assessment can reduce unnecessary testing and animal use.

🔗

Part of the Compliance Chain

Evidence feeds your risk file (ISO 14971) and technical documentation under your ISO 13485 system.

SECTION 2

2 Key Benefits of ISO 10993 Conformity

A well-run biological evaluation protects patients and speeds regulatory review. Gains depend on device type and how early you start, so plan evaluation during design, not at the end.

🏷️

Faster Market Access

A complete evaluation reduces regulator and notified body questions and avoids late-stage retesting.

Commercial
💰

Avoided Rework

Early material and chemistry choices prevent costly redesigns after a failed test.

Operational
🔗

Supplier Confidence

Biocompatibility data from material suppliers makes qualification of components easier.

Partnership
📊

Evidence-Based Decisions

Chemical characterisation and toxicological assessment support defensible, data-driven conclusions.

Analytical
👥

Clear Responsibilities

The plan defines who owns materials, testing, assessment and sign-off.

People
📋

Regulatory & Risk Alignment

Links biological hazards to your risk management and post-market activities.

Compliance
SECTION 3

3 The Parts of the ISO 10993 Series

The series is large and parts are updated at different times. The table lists the main parts used in most programmes. Always confirm current editions and any European (EN) adoptions on the official catalogues.

PartTitle / FocusWhat It Means for You
ISO 10993-1Evaluation and testing within a risk management processFramework: categorise the device, identify endpoints, plan the evaluation.
ISO 10993-3Genotoxicity, carcinogenicity and reproductive toxicityTests for genetic and long-term effects where required.
ISO 10993-4Interactions with bloodHaemocompatibility testing for blood-contacting devices.
ISO 10993-5In vitro cytotoxicityA common first screening test of cell toxicity.
ISO 10993-6Local effects after implantationEvaluation of tissue response to implanted materials.
ISO 10993-10Skin sensitisationAssesses allergic response potential.
ISO 10993-11Systemic toxicityAssesses effects beyond the contact site.
ISO 10993-12Sample preparation and reference materialsHow to prepare device samples and extracts for testing.
ISO 10993-17Toxicological risk assessment of constituentsEstablishes allowable limits for leachable substances.
ISO 10993-18Chemical characterisation of materialsIdentifies and quantifies chemical constituents; may replace some biological tests.
ISO 10993-23Tests for irritationCovers irritation testing, including in vitro approaches.
SECTION 4

4 Step 1: Preparation, Device Categorisation & Planning

🏗️ Building the Foundation

Preparation defines what you are evaluating. Categorise the device by nature of body contact (surface, external communicating or implant) and contact duration (limited, prolonged or long-term), because these determine the biological endpoints to address. Allow 2–6 weeks.

1.1

Get Trained on ISO 10993

Make sure regulatory, quality and R&D staff understand Part 1 and the risk-based approach.

1.2

Secure Management Support

Biological evaluation needs budget, lab capacity and design-change authority. Align with your ISO 13485 management review.

1.3

Describe the Device & Materials

List all materials, additives, coatings, processing aids, sterilisation methods and manufacturing residues.

1.4

Categorise Body Contact & Duration

Determine contact type and cumulative duration, including multiple uses.

1.5

Gap Analysis

Compare existing data (supplier certificates, literature, prior tests) with required endpoints.

1.6

Plan the Project

Assign owners, laboratories and timelines, and set up links to the risk file.

💡 Pro Tip: Start in Design

Choosing materials with known biocompatibility history can remove entire test categories. If a change in material or process occurs later, reassess the evaluation. See also ISO 14971 for managing design changes through risk.

SECTION 5

5 Step 2: Documentation, Biological Evaluation Plan

Documentation shows an evaluator how you reached your conclusions. Keep it traceable: each endpoint should link to evidence or a justification.

DocumentDescriptionKey Consideration
Biological Evaluation Plan (BEP)Defines device, categorisation, endpoints, existing data and planned testing.Approve before testing starts and update when the design changes.
Material & Process DescriptionFull list of materials, suppliers and manufacturing and sterilisation steps.Include residues such as cleaning agents and EO.
Chemical Characterisation ReportIdentifies extractables and leachables, often per Part 18.Can reduce or replace some biological tests.
Toxicological Risk AssessmentAssesses chemical constituents against allowable limits, often per Part 17.Performed by a qualified toxicologist.
Test ReportsLaboratory results for selected endpoints.Check laboratory accreditation and test method versions.
Biological Evaluation Report (BER)Summarises data, justifies conclusions and states residual risk.Must be linked to the risk management file.
Supplier DocumentationMaterial declarations and change-notification agreements.Use verified suppliers; see business verification.
RecordsChange history, reviews, approvals and re-evaluation triggers.Keep retrievable under document control.
💡 Documentation Best Practices

DO: justify every endpoint, whether tested or not.

DON’T: copy supplier certificates without checking that they match your final, sterilised device.

Use templates for the BEP and BER and keep them consistent with your technical file. Contract clarity matters too; see manufacturer-distributor contracts.

SECTION 6

6 Step 3: Testing, Generating the Evidence

Testing should be targeted. Start from the plan, use chemical characterisation to reduce the number of tests where acceptable, and use competent laboratories.

🧪

Confirm the Endpoints

Typical endpoints include cytotoxicity, sensitisation, irritation, systemic toxicity, genotoxicity, haemocompatibility and implantation, depending on category.

Planning
🧫

Prepare Representative Samples

Test final, finished, sterilised devices or justified representative samples, following Part 12.

Samples
🔬

Chemical Characterisation First

Run extractables studies to identify risks early and potentially avoid animal tests.

Chemistry
🏢

Select Accredited Laboratories

Use ISO/IEC 17025-accredited, GLP-compliant laboratories where required.

Laboratories
🐁

Minimise Animal Testing

Follow the principle of replacement, reduction and refinement and consider validated in vitro methods.

Ethics
📁

Control the Data

Keep raw data, protocols, deviations and final reports under document control.

Compliance
⚠️

Act on Failures

Investigate root cause, assess material or process changes, and retest as needed.

Corrective Action
SECTION 7

7 Step 4: Internal Review, Gap Closure

🔍 Verifying Your Evidence

Before reporting, review the complete evidence set against the plan. Check that every endpoint is addressed, that tested samples represent the final device, that toxicological conclusions are supported, and that residual risks are fed into your risk management file. Reviewers should be independent of the people who generated the data.

📋

Plan vs Evidence

Confirm each planned endpoint has data or a documented justification.

👤

Qualified Reviewers

Involve toxicologists, regulatory and quality staff with relevant competence.

🔎

Check Representativeness

Verify that samples reflect final materials, processing and sterilisation.

✅

Close Gaps

Resolve open findings and repeat tests where needed before reporting.

📈

Update the Risk File

Transfer conclusions and residual risks to your ISO 14971 file.

📄

Independent Check

An external regulatory consultant can pre-review the report before submission.

SECTION 8

8 Step 5: Reporting & Regulatory Submission

The biological evaluation report (BER) is the final record. It is normally reviewed by a notified body or regulator as part of your technical documentation. There is no separate ISO 10993 certificate; acceptance is through regulatory review.

StageWhat HappensKey Focus
Finalise the BERSummarise data, justify conclusions and state residual risk.Traceability from endpoint to evidence.
Integrate with Risk FileLink conclusions to hazards and controls.Consistency with ISO 14971
Quality System ReviewConfirm procedures and records meet ISO 13485 requirements.Document control and change management.
Regulatory ReviewTechnical documentation reviewed by a notified body or regulator.Responding to questions with evidence.
MaintenanceRe-evaluate on design, material, supplier or process changes and from post-market data.Ongoing conformity.
💡 Preparing for Review

Keep a clear index of the evidence, make the toxicologist available for questions and prepare answers on material changes. Related standards you may be asked about include ISO 9001 and ISO 14001.

SECTION 9

9 Costs & Timeline: What to Expect

These ranges are indicative only. Get written quotes and a laboratory schedule before committing to a launch date.

FactorImpact on CostImpact on Timeline
Contact Type & DurationImplants and long-term devices need more endpoints.Long-term devices may need 12–18 months or more.
Existing DataStrong supplier and historical data reduces testing.Can cut months from the plan.
Number of MaterialsMore materials increase characterisation effort.Longer extraction and analysis schedules.
Chemical CharacterisationAdds upfront cost but may avoid biological tests.Typically several weeks to months.
In Vivo StudiesSubstantially higher cost.Study length and lab availability drive timing.
Consultant SupportAdds fees; reduces rework.Experienced toxicologists shorten review cycles.
📋 Reuse Your Management System

If you hold ISO 13485 or ISO 9001, reuse document control, supplier control and CAPA processes for the evaluation.

SECTION 10

10 How to Choose a Testing Laboratory

🏛️

Accreditation

Look for ISO/IEC 17025 accreditation covering the test methods you need, and GLP compliance where required.

🧪

Device Experience

Choose labs familiar with your device type and sterilisation method.

📋

Regulatory Acceptance

Confirm that your regulator or notified body accepts the laboratory’s reports.

💰

Cost & Value

Compare scope, turnaround, retest policy and report quality.

🌐

Global Capability

Multi-region submissions may benefit from labs with international recognition.

🤝

Communication

Responsive study directors and clear protocols reduce delays. See partnership evaluation criteria.

SECTION 11

11 ISO 10993 and Risk Management (ISO 14971)

⚖️ Biological Risk Within the Risk File

ISO 14971 is the risk management standard for medical devices, and ISO 10993-1 places biological evaluation inside that process. Biological hazards such as toxicity, sensitisation and degradation products are identified, evaluated and controlled, and residual risk is judged acceptable or not. Both rely on a quality system like ISO 13485, and information security of device and test data may fall under ISO 27001 and ISO 27701.

🔍

Identify Biological Hazards

Derive hazards from materials, additives, processing and use conditions.

📊

Estimate & Evaluate

Use test data and toxicological assessment to judge severity and acceptability.

🛡️

Control

Change materials, processes or labelling, or add controls where risk is not acceptable.

🔄

Monitor

Use post-market data and changes to trigger re-evaluation. Also see ISO 22301 for supply continuity and ISO 45001 for laboratory safety.

SECTION 12

12 Common Mistakes & How to Avoid Them

📋

Testing Without a Plan

Running a standard battery wastes money. Avoid: write the BEP first.

🏛️

Ignoring Material Changes

A supplier change can invalidate data. Avoid: require change notification and reassess.

📖

Testing Non-Representative Samples

Unsterilised or prototype samples may not reflect the final device. Avoid: justify representativeness.

🔄

Treating It as Test-Only

Reports without toxicological assessment can be rejected. Avoid: integrate chemistry and risk assessment.

🎓

Weak Supplier Control

Unverified suppliers undermine evidence; see global partner service. Avoid: qualify suppliers formally.

📊

Leaving the Risk File Unlinked

Conclusions must flow into the risk file. Avoid: cross-reference clearly. See risk allocation.

SECTION 13

13 How GTsetu Supports Your Compliance Journey

🔗 GTsetu, Verified B2B Platform

Connect with Verified Partners & Build Quality Supply Chains

A sound biological evaluation depends on reliable materials and suppliers. GTsetu complements your compliance work by connecting you with verified manufacturers, distributors and suppliers of medical device materials and components.

✅
Verified Company ProfilesEvery company is verified on 6 key data points (Name, Address, Registration Number, Company Status, Company Type, Date of Incorporation) using government tie-ups.
🕵️
Anonymous DiscoveryBrowse verified partner profiles without revealing your identity until you are ready to engage.
📄
Built-In NDA WorkflowDigital mutual NDA with timestamped signatures before sensitive material, formulation or commercial data is shared.
🔐
Encrypted Document WorkspaceAES-256 encryption at rest, TLS in transit, role-based access and a full audit trail for secure exchange of specifications and contracts.
🚫
Zero Broker CommissionGTsetu charges zero commission on any partnership formed.
🌏
Global Network of Verified PartnersAccess verified manufacturers, distributors and suppliers across 100+ countries.
FAQ

? Frequently Asked Questions

QWhat is EN ISO 10993 and why is it important?
EN ISO 10993 is the series of standards for the biological evaluation of medical devices. It describes how to assess whether materials and devices are safe for contact with the human body, as part of a risk management process. It is important because regulators and notified bodies expect a documented biological evaluation for devices that touch the body. It works alongside ISO 14971 risk management and a ISO 13485 quality system.
QIs there an ISO 10993 certificate?
Not in the way ISO 9001 has one. ISO 10993 is a series of evaluation and test standards, so you show conformity through a documented biological evaluation (plan, test data, toxicological assessment and report), usually reviewed during regulatory submissions or by a notified body. Always confirm requirements with your regulator or notified body.
QWhat are the 5 main steps to demonstrate ISO 10993 conformity?
(1) Preparation: define the device, materials, body contact and duration. (2) Documentation: write the biological evaluation plan and gather material and chemical characterisation. (3) Testing: run only the tests needed, at competent laboratories. (4) Internal Review: assess the data, close gaps and update the risk file. (5) Reporting and Submission: issue the biological evaluation report and include it in your regulatory file.
QHow long does biological evaluation take?
It depends on device type and contact duration. As an indicative guide, a low-risk surface-contact device with good material data may take 3-6 months, while implants or long-term devices with chemical characterisation and in vivo studies can take 12-18 months or more. Laboratory scheduling and test duration are usually the critical path.
QHow much does ISO 10993 testing cost?
Costs vary widely with device category, number of endpoints, sample preparation and laboratory. Simple in vitro tests can cost a few thousand US dollars, while a full programme for an implant can reach well into six figures. Always request written quotes and ask whether a toxicological risk assessment can reduce testing.
QWhich documents are required?
Typical documents include a biological evaluation plan (BEP), material and manufacturing process descriptions, chemical characterisation reports, toxicological risk assessment, test reports from accredited laboratories, and a biological evaluation report (BER) linked to your risk management file.
QHow do I choose a testing laboratory?
Select a laboratory with ISO/IEC 17025 accreditation for the relevant tests and good laboratory practice (GLP) compliance where required. Check experience with your device type, report quality and turnaround. Apply the same discipline as in your partnership evaluation criteria.

Related Articles

ISO 9001 Certification

Quality management foundation for document control and audits.

ISO 14001 Certification

Environmental management for manufacturing and sterilisation processes.

ISO 13485 Certification

Medical device quality management system that houses your biological evaluation.

ISO 27001 Certification

Information security for design, test and supplier data.

ISO 45001 Certification

Occupational health and safety, including laboratory and production safety.

ISO 22000 Certification

Food safety management, relevant to contact-material suppliers.

ISO 20000 Certification

IT service management supporting regulated data systems.

ISO 27701 Certification

Privacy information management for personal and clinical data.

ISO 26262 Certification

Functional safety for automotive and device electronics partners.

ISO 22301 Certification

Business continuity for resilient medical device supply chains.

ISO 14971 Certification

Risk management for medical devices, the framework for ISO 10993-1.

Partnership Evaluation Criteria

Framework for evaluating and selecting business partners.

Ready to Build a Quality-Driven Supply Chain?

Connect with verified manufacturers, distributors and suppliers on GTsetu: compliance-backed verification, anonymous discovery, built-in NDA workflows and zero broker commissions.

Find Verified Partners Free →Browse Verified Companies